CLSN · Celsion Corp

-

Please sign in to comment on CLSN

1 Comment

Admin

4 years, 1 month ago

Celsion Corporation is currently in a long term uptrend where the price is trading 1.0% above its 200 day moving average.

From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 93.3.

Celsion Corporation's total revenue sank by 0.0% to $125K since the same quarter in the previous year.

Its net income has increased by 2.9% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 33.6% to $-4M since the same quarter in the previous year.

Based on the above factors, Celsion Corporation gets an overall score of 4/5.

ISIN	US15117N6022
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology & Medical Research

Beta	2.26
Market Cap	14M
PE Ratio	None
Target Price	27
Dividend Yield	0.0%

ABOUT

Celsion Corp

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

CLSN · Celsion Corp

-

Celsion Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Celsion Corp using a moving average strategy